

63 Zillicoa Street Asheville, NC 28801 © Genova Diagnostics Geffects

Patient: SAMPLE PATIENT

DOB: Sex:

MRN:

209 GI Effects [™] Fundamentals - St			
Iethodology: GC/MS, Automated Chemistry, EIA	Result	QUINTILE DISTRIBUTION 1st 2nd 3rd 4th 5th	Reference Range
Pancreatic Elastase 1 †	158 L	100 200	>200 mcg/g
Products of Protein Breakdown (Total*) (Valerate, Isobutyrate, Isovalerate)	6.0		1.8-9.9 micromol/g
Fecal Fat (Total*)	19.5		3.2-38.6 mg/g
Triglycerides	1.1	· · · · · · · · · · · · · · · · · · ·	0.3-2.8 mg/g
Long-Chain Fatty Acids	12.9		1.2-29.1 mg/g
Cholesterol	0.5	► + + + + +	0.4-4.8 mg/g
Phospholipids	5.0		0.2-6.9 mg/g
Calprotectin †	145 H	50 120	<=50 mcg/g
Eosinophil Protein X (EPX)†	4.9 H	1.1 4.6	<=4.6 mcg/g
	Gut Mic	crobiome Metabolites	
Metabolic			
Short-Chain Fatty Acids (SCFA) (Total*) (Acetate, n-Butyrate, Propionate)	81.3	<u> </u>	>=23.3 micromol/g
n-Butyrate Concentration	18.1		>=3.6 micromol/g
n-Butyrate %	22.3		11.8-33.3 %
Acetate %	63.1		48.1-69.2 %
Propionate %	14.6		<=29.3 %
Beta-glucuronidase	2,297		368-6,266 U/g

*Total value is equal to the sum of all measurable parts.

†These results are not represented by quintile values.

Tests were developed and their performance characteristics determined by Genova Diagnostics. Unless otherwise noted with Ø, the assays have not been cleared by the U.S. Food and Drug Administration.

NG

No Growth

Methodology: Culture/MALDI-TOF MS, Automated and Manual Biochemical Methods, Vitek® 2 System Microbial identification and Antibiotic susceptibility

Ρ

Pathogen

Gastrointestinal Microbiome (Culture)

Human microflora is influenced by environmental factors and the competitive ecosystem of the organisms in the GI tract. Pathogenic significance should be based upon clinical symptoms.

Microbiology Legend

PP

Potential


NP

Non-

Additional Bacteria

Non-Pathogen: Organisms that fall under this category are those that constitute normal, commensal flora, or have not been recognized as etiological agents of disease.

Potential Pathogen: Organisms that fall under this category are considered potential or opportunistic pathogens when present in heavy growth. **Pathogen:** The organisms that fall under this category have a well-recognized mechanism of pathogenicity in clinical literature and are considered significant regardless of the quantity that appears in the culture.



** Indicates testing performed by Genova Diagnostics, Inc. 63 Zi llicoa St., Ash eville, NC 28801-0174 A. L. Peace-Brewer, PhD, D(ABMLI), Lab Director - CLI A Lic. #34D0655571 - Medicare Lic. #34-8475

	Ac	ditional Results		
Methodology: Fecal Immunochemic	Methodology: Fecal Immunochemical Testing (FIT)			
	Result	Expected Value		
Fecal Occult Blood	Negative	Negative		
Color††	Green			
Consistency††	Formed/Normal			

††Results provided from patient input.

Tests were developed and their performance characteristics determined by Genova Diagnostics. Unless otherwise noted with , the assays have not been cleared by the U.S. Food and Drug Administration.

Reference: 1. Scheffler L, et al. Widely Used Commercial ELISA Does Not Detect Precursor of Haptoglobin2, but Recognizes Properdin as a Potential Second Member of the Zonulin Family. *Front Endocrinol.* 2018;9:22. Methodology: Vitek 2® System Microbial Antibiotic susceptibility, Manual Minimum Inhibition Concentration

Mycology Sensitivity

Azole Antifungals

/ Loro / Intinangalo						
Candida species	R	I.	S-DD	S		NI
Fluconazole				0.5		
Voriconazole				<=0.008		
Nystatin	=50					
Natural Agents						
Candida species		DN .			I	HIGH INHIBITION
Berberine						
Caprylic Acid						
Garlic						
Undecylenic Acid						
Plant tannins						
Uva-Ursi						

Prescriptive Agents:

The R (Resistant) category implies isolate is not inhibited by obtainable levels of pharmaceutical agent.

The I (Intermediate) category includes isolates for which the minimum inhibition concentration (MIC) values usually approach obtainable pharmaceutical agent levels and for which response rates may be lower than for susceptible isolates.

The S-DD (Susceptible-Dose Dependent) category implies clinical efficacy when higher than normal dosage of a drug can be used and maximal concentration achieved.

The S (Susceptible) column implies that isolates are inhibited by the usually achievable concentrations of the pharmaceutical agent.

NI (No Interpretive guidelines established) category is used for organisms that currently do not have established guidelines for MIC interpretation.

Refer to published pharmaceutical guidelines for appropriate dosage therapy.

Nystatin and Natural Agents:

Results for Nystatin are being reported with natural antifungals in this category in accordance with laboratory guidelines for reporting sensitivities. In this assay, inhibition is defined as the reduction level on organism growth as a direct result of inhibition by a natural substance. The level of inhibition is an indicator of how effective the substance was at limiting the growth of an organism in an in vitro environment. High inhibition indicates a greater ability by the substance to limit growth, while Low Inhibition a lesser ability to limit growth. The designated natural products should be considered investigational in nature and not be viewed as standard clinical treatment substances.

Methodology: Vitek 2® System Microbial Antibiotic susceptibility, Manual Minimum Inhibition Concentration

Bacteria Sensitivity

Prescriptive Agents

Klebsiella pneumoniae	R	S-DD	S	NI
Ampicillin	R			
Amox./Clavulanic Acid			S	
Cephalothin			S	
Ciprofloxacin			S	
Tetracycline			S	
Trimethoprim/Sulfa			S	
latural Agents				

Klebsiella pneumoniae	LOW INHIBITION	HIGH INHIBITION
Berberine		
Oregano		
Plant Tannins		
Uva-Ursi		

Prescriptive Agents:

The R (Resistant) category implies isolate is not inhibited by obtainable levels of pharmaceutical agent.

The I (Intermediate) category includes isolates for which the minimum inhibition concentration (MIC) values usually approach obtainable pharmaceutical agent levels and for which response rates may be lower than for susceptible isolates.

The S-DD (Susceptible-Dose Dependent) category implies clinical efficacy when higher than normal dosage of a drug can be used and maximal concentration achieved.

The S (Susceptible) column implies that isolates are inhibited by the usually achievable concentrations of the pharmaceutical agent.

NI (No Interpretive guidelines established) category is used for organisms that currently do not have established guidelines for MIC interpretation.

Refer to published pharmaceutical guidelines for appropriate dosage therapy.

Natural Agents:

In this assay, inhibition is defined as the reduction level on organism growth as a direct result of inhibition by a substance. The level of inhibition is an indicator of how effective the substance was at limiting the growth of an organism in an in vitro environment. High inhibition indicates a greater ability by the substance to limit growth, while Low Inhibition a lesser ability to limit growth. The designated natural products should be considered investigational in nature and not be viewed as standard clinical treatment substances.